Therapeutic exploitation of the physiological and molecular genetic alterations in head and neck cancer

Clinical Cancer Research

Volumn 9, Issue 12, 2003, Pages 4287-4295

  Le, Quynh Thu ^a   Giaccia, Amato J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED CANCER; CANCER INHIBITION; CANCER PREVENTION; CANCER SURVIVAL; HEAD AND NECK CANCER; METASTASIS; MOLECULAR GENETICS; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR VASCULARIZATION;

ANTIGENS, NEOPLASM; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; MOLECULAR BIOLOGY; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141925980     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (92)

1. Forastiere, A., Koch, W., Trotti, A., and Sidransky, D. Head and neck cancer. N. Engl. J. Med., 345: 1890-1900, 2001.
2. Califano, J., van der Riet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., Corio, R., Lee, D., Greenberg, B., Koch, W., and Sidransky, D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res., 56: 2488-2492, 1996.
3. Partridge, M., Pateromichelakis, S., Phillips, E., Emilion, G. G., A'Hern, R. P., and Langdon, J. D. A case-control study confirms that microsatellite assay can identify patients at risk of developing oral squamous cell carcinoma within a field of cancerization. Cancer Res., 60: 3893-3898, 2000.
4. Gollin, S. M. Chromosomal alterations in squamous cell carcinomas of the head and neck: window to the biology of disease. Head Neck, 23: 238-253, 2001.
5. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., 3rd, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Wash. DC), 264: 436-440, 1994.
6. Jeannon, J. P., and Wilson, J. A. Cyclins, cyclin-dependent kinases, cyclin-dependent kinase inhibitors and their role in head and neck cancer. Clin. Otolaryngol., 23: 420-424, 1998.
7. Roz, L., Wu, C. L., Porter, S., Scully, C., Speight, P., Read, A., Sloan, P., and Thakker, N. Allelic imbalance on chromosome 3p in oral dysplastic lesions: an early event in oral carcinogenesis. Cancer Res., 56: 1228-1231, 1996.
8. Gotte, K., Hadaczek, P., Coy, J. F., Wirtz, H. W., Riedel, F., Neubauer, J., and Hormann, K. Fhit expression is absent or reduced in a subset of primary head and neck cancer. Anticancer Res, 20: 1057-1060, 2000.
9. Boyle, J. O., Hakim, J., Koch, W., van der Riet, P., Hruban, R. H., Roa, R. A., Correo, R., Eby, Y. J., Ruppert, J. M., and Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 53: 4477-4480, 1993.
10. Hibi, K., Trink, B., Patturajan, M., Westra, W. H., Caballero, O. L., Hill, D. E., Ratovitski, E. A., Jen, J., and Sidransky, D. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. USA, 97: 5462-5467, 2000.
11. Akervall, J. A., Michalides, R. J., Mineta, H., Balm, A., Borg, A., Dictor, M. R., Jin, Y., Loftus, B., Mertens, F., and Wennerberg, J. P. Amplification of cyclin D1 in squamous cell carcinoma of the head and neck and the prognostic value of chromosomal abnormalities and cyclin D1 overexpression. Cancer (Phila.), 79: 380-389, 1997.
12. Schuuring, E., van Damme, H., Schuuring-Scholtes, E., Verhoeven, E., Michalides, R., Geelen, E., de Boer, C., Brok, H., van Buuren, V., and Kluin, P. Characterization of the EMS1 gene and its product, human Cortactin. Cell Adhes. Commun., 6: 185-209, 1998.
13. Namazie, A., Alavi, S., Olopade, O. I., Pauletti, G., Aghamohammadi, N., Aghamohammadi, M., Gornbein, J. A., Calcaterra, T. C., Slamon, D. J., Wang, M. B., and Srivatsan, E. S. Cyclin D1 amplification and p16(MTS1/CDK41) deletion correlate with poor prognosis in head and neck tumors. Laryngoscope, 112: 472-481, 2002.
14. Rodrigo, J. P., Garcia, L. A., Ramos, S., Lazo, P. S., and Suarez, C. EMS1 gene amplification correlates with poor prognosis in squamous cell carcinomas of the head and neck. Clin. Cancer Res., 6: 3177-3182, 2000.
15. Schuuring, E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes - a review. Gene, 159: 83-96, 1995.
16. Brizel, D. M., Dodge, R. K., Clough, R. W., and Dewhirst, M. W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol., 53: 113-117, 1999.
17. Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., and Giaccia, A. J. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature (Lond.), 379: 88-91, 1996.
18. Brown, J. M. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumors. Br. J. Cancer, 67: 1163-1170, 1993.
19. Rischin, D., Peters, L., Hicks, R., Hughes, P., Fisher, R., Hart, R., Sexton, M., D'Costa, I., and von Roemeling, R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol., 19: 535-542, 2001.
20. Pinto, H. A., Le, Q. T., Terris, D. J., Bloch, D., Goffinet, D. R., and Brown, J. M. Randomized trial of tirapazamine/cisplatin/fluorouracil versus cisplatin/fluorouracil for organ preservation in advanced resectable head and neck cancer (abstract # 904). Proc. Am. Soc. Clin. Oncol., 227a, 2002.
21. Kaanders, J. H., Pop, L. A., Marres, H. A., Bruaset, I., van den Hoogen, F. J., Merkx, M. A., and van der Kogel, A. J. ARCON: experience in 215 patients with advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys., 52: 769-778, 2002.
22. Dassonville, O., Formento, J. L., Francoual, M., Ramaioli, A., Santini, J., Schneider, M., Demard, F., and Milano, G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J. Clin. Oncol., 11: 1873-1878, 1993.
23. Grandis, J. R., Melhem, M. F., Gooding, W. E., Day, R., Holst, V. A., Wagener, M. M., Drenning, S. D., and Tweardy, D. J. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst., 90: 824-832, 1998.
24. Ang, K. K., Berkey, B. A., Tu, X., Zhang, H. Z., Katz, R., Hammond, E. H., Fu, K. K., and Milas, L. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res., 62: 7350-7356, 2002.
25. Huang, S. M., Li, J., Armstrong, E. A., and Harari, P. M. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res., 62: 4300-4306, 2002.
26. Sirotnak, F. M., Zakowski, M. F., Miller, V. A., Scher, H. I., and Kris, M. G. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res., 6: 4885-4892, 2000.
27. Lammering, G., Valerie, K., Lin, P. S., Mikkelsen, R. B., Contessa, J. N., Feden, J. P., Farnsworth, J., Dent, P., and Schmidt-Ullrich, R. K. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin. Cancer Res., 7: 682-690, 2001.
28. Lammering, G., Hewit, T. H., Hawkins, W. T., Contessa, J. N., Reardon, D. B., Lin, P. S., Valerie, K., Dent, P., Mikkelsen, R. B., and Schmidt-Ullrich, R. K. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J. Natl. Cancer Inst., 93: 921-929, 2001.
29. Robert, F., Ezekiel, M. P., Spencer, S. A., Meredith, R. F., Bonner, J. A., Khazaeli, M. B., Saleh, M. N., Carey, D., LoBuglio, A. F., Wheeler, R. H., Cooper, M. R., and Waksal, H. W. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J. Clin. Oncol., 19: 3234-3243, 2001.
30. Baselga, J., Trigo, J. M., Bourhis, J., Tortochaux, J., Cortes-Funes, H., Hitt, R., Gascon, P., Muesser, M., Harstrick, A., and Eckardt, A. Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen (abstract # 900). Proc. Am. Soc. Clin. Oncol., 226a, 2002.
31. Kies, M. S., Arquette, M. A., Nabell, L., Quinn, D., Shin, D., Needle, M. N., Waksal, H. W., Hong, W. K., and Herbst, R. S. Final report of the efficacy and safety of the anti-epidermal growth factor antibody Erbitux (IMC-C225), in combination with cisplatin in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN) refractory to cisplatin containing therapy (abstract #925). Proc. Am. Soc. Clin. Oncol., 232a, 2002.
32. Burtness, B. A., Li, Y., Flood, W., Mattar, B. I., and Forastiere, A. A. Phase III trial comparing cisplatin (c) + placebo to C + antiepidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC; abstract #901). Proc. Am. Soc. Clin. Oncol., 226a, 2002.
33. Mineta, H., Miura, K., Ogino, T., Takebayashi, S., Misawa, K., and Ueda, Y. Vascular endothelial growth factor (VEGF) expression correlates with p53 and ki-67 expressions in tongue squamous cell carcinoma. Anticancer Res., 22: 1039-1044, 2002.
34. P, O. c., Rhys-Evans, P., and Eccles, S. A. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer (Phila.), 92: 556-568, 2001.
35. Qian, C. N., Zhang, C. Q., Guo, X., Hong, M. H., Cao, S. M., Mai, W. Y., Min, H. Q., and Zeng, Y. X. Elevation of serum vascular endothelial growth factor in male patients with metastatic nasopharyngeal carcinoma. Cancer (Phila.), 88: 255-261, 2000.
36. Smith, B. D., Smith, G. L., Carter, D., DiGiovanna, M. P., Kasowitz, K. M., Sasaki, C. T., and Haffty, B. G. Molecular marker expression in oral and oropharyngeal squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg., 127: 780-785, 2001.
37. Artese, L., Rubini, C., Ferrero, G., Fioroni, M., Santinelli, A., and Piattelli, A. Microvessel density (MVD) and vascular endothelial growth factor expression (VEGF) in human oral squamous cell carcinoma. Anticancer Res., 21: 689-695, 2001.
38. Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, K., Pastorek, J., Wykoff, C. C., Gatter, K. C., and Harris, A. L. Hypoxia-regulated carbonic anhydrase-9 (CA9) relates to poor vascularization and resistance of squamous cell head and neck cancer to chemoradiotherapy. Clin. Cancer Res., 7: 3399-3403, 2001.
39. Lopez-Graniel, C. M., Tamez de Leon, D., Meneses-Garcia, A., Gomez-Ruiz, C., Frias-Mendivil, M., Granados-Garcia, M., and Barrera-Franco, J. L. Tumor angiogenesis as a prognostic factor in oral cavity carcinomas. J. Exp. Clin. Cancer Res., 20: 463-468, 2001.
40. O'Reilly, M. S., Holmgren, L., Chen, C., and Folkman, J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2: 689-692, 1996.
41. O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., and Folkman, J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88: 277-285, 1997.
42. Asano, M., Yukita, A., Matsumoto, T., Kondo, S., and Suzuki, H. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor12l. Cancer Res., 55: 5296-5301, 1995.
43. Goldman, C. K., Kendall, R. L., Cabrera, G., Soroceanu, L., Heike, Y., Gillespie, G. Y., Siegal, G. P., Mao, X., Bett, A. J., Huckle, W. R., Thomas, K. A., and Curiel, D. T. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl. Acad. Sci. USA, 95: 8795-8800, 1998.
44. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., and Ferrara, N. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature (Lond.), 362: 841-844, 1993.
45. Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D., and Johnson, R. S. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res., 59: 1592-1598, 1999.
46. Tseng, J. E., Glisson, B. S., Khuri, F. R., Shin, D. M., Myers, J. N., El-Naggar, A. K., Roach, J. S., Ginsberg, L. E., Thall, P. F., Wang, X., Teddy, S., Lawhorn, K. N., Zentgraf, R. E., Steinhaus, G. D., Pluda, J. M., Abbruzzese, J. L., Hong, W. K., and Herbst, R. S. Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer (Phila.), 92: 2364-2373, 2001.
47. Thomas, J. P., Arzoomanian, R. Z., Alberti, D., Marnocha, R., Lee, F., Friedl, A., Tutsch, K., Dresen, A., Geiger, P., Pluda, J., Fogler, W., Schiller, J. H., and Wilding, G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 21: 223-231, 2003.
48. Herbst, R. S., Hess, K. R., Tran, H. T., Tseng, J. E., Mullani, N. A., Charnsangavej, C., Madden, T., Davis, D. W., McConkey, D. J., O'Reilly, M. S., Ellis, L. M., Pluda, J., Hong, W. K., and Abbruzzese, J. L. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J. Clin. Oncol., 20: 3792-3803, 2002.
49. Eder, J. P., Jr., Supko, J. G., Clark, J. W., Puchalski, T. A., Garcia-Carbonero, R., Ryan, D. P., Shulman, L. N., Proper, J., Kirvan, M., Rattner, B., Connors, S., Keogan, M. T., Janicek, M. J., Fogler, W. E., Schnipper, L., Kinchla, N., Sidor, C., Phillips, E., Folkman, J., and Kufe, D. W. Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily. J. Clin. Oncol., 20: 3772-3784, 2002.
50. Herbst, R. S., Mullani, N. A., Davis, D. W., Hess, K. R., McConkey, D. J., Charnsangavej, C., O'Reilly, M. S., Kim, H. W., Baker, C., Roach, J., Ellis, L. M., Rashid, A., Pluda, J., Bucana, C., Madden, T. L., Tran, H. T., and Abbruzzese, J. L. Development of biologic markers of response and assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J. Clin. Oncol., 20: 3804-3814, 2002.
51. Mundhenke, C., Thomas, J. P., Wilding, G., Lee, F. T., Kelzc, F., Chappell, R., Neider, R., Sebree, L. A., and Friedl, A. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin. Cancer Res., 7: 3366-3374, 2001.
52. Davis, P. D., Dougherty, G. J., Blakey, D. C., Galbraith, S. M., Tozer, G. M., Holder, A. L., Naylor, M. A., Nolan, J., Stratford, M. R., Chaplin, D. J., and Hill, S. A. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res., 62: 7247-7253, 2002.
53. Chaplin, D. J., Pettit, G. R., Parkins, C. S., and Hill, S. A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br. J. Cancer. 27 (Suppl.): S86-S88, 1996.
54. Dark, G. G., Hill, S. A., Prise, V. E., Tozer, G. M., Pettit, G. R., and Chaplin, D. J. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res., 57: 1829-1834, 1997.
55. Denekamp, J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev., 9: 267-282, 1990.
56. Hill, S., Williams, K. B., and Denekamp, J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur. J. Cancer Clin. Oncol., 25: 1419-1424, 1989.
57. Murata, R., Overgaard, J., and Horsman, M. R. Comparative effects of combretastatin A-4 disodium phosphate and 5, 6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int. J. Radiat. Biol., 77: 195-204, 2001.
58. Thorpe, P. E., Chaplin, D. J., and Blakey, D. C. The first international conference on vascular targeting: meeting overview. Cancer Res., 63: 1144-1147, 2003.
59. Murata, R., Overgaard, J., and Horsman, M. R. Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5, 6-dimethylxanthenone-4-acetic acid. Int. J. Hyperthermia, 17: 508-519, 2001.
60. Murata, R., Siemann, D. W., Overgaard, J., and Horsman, M. R. Improved tumor response by combining radiation and the vascular-damaging drug 5, 6-dimethylxanthenone-4-acetic acid. Radiat. Res., 156: 503-509, 2001.
61. Das, N., Majumder, J., and DasGupta, U. B. ras gene mutations in oral cancer in eastern India. Oral Oncol., 36: 76-80, 2000.
62. Gupta, A. K., McKenna, W. G., Weber, C. N., Feldman, M. D., Goldsmith, J. D., Mick, R., Machtay, M., Rosenthal, D. I., Bakanauskas, V. J., Cerniglia, G. J., Bernhard, E. J., Weber, R. S., and Muschel, R. J. Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin. Cancer Res., 8: 885-892, 2002.
63. Moasser, M. M., Sepp-Lorenzino, L., Kohl, N. E., Oliff, A., Balog, A., Su, D. S., Danishefsky, S. J., and Rosen, N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc. Natl. Acad. Sci. USA, 95: 1369-1374, 1998.
64. Kies, M. S., Clayman, G. L., El-Naggar, A. K., Bishop, W. R., Baum, C., Kerschmeier, P., Bohanon, S., Patton, R., Wright, S., Lu, C., Mao, L., Sabichi, A., Hong, W. K., and Khuri, F. R. Induction therapy with SCH66336, a farnesyltransferase inhibitor in squamous cell carcinoma (SCC) of the head and neck (abstract #896). Proc. Am. Soc. Clin. Oncol., 225a, 2001.
65. Hahn, S. M., Bernhard, E. J., Regine, W., Mohiuddin, M., Haller, D. G., Stevenson, J. P., Smith, D., Pramanik, B., Tepper, J., DeLaney, T. F., Kiel, K. D., Morrison, B., Deutsch, P., Muschel, R. J., and McKenna, W. G. A Phase I trial of the farnesyltransferase inhibitor L-778, 123 and radiotherapy for locally advanced lung and head and neck cancer. Clin. Cancer Res., 8: 1065-1072, 2002.
66. Cohen-Jonathan, E., Evans, S. M., Koch, C. J., Muschel, R. J., McKenna, W. G., Wu, J., and Bernhard, E. J. The farnesyltransferase inhibitor L744, 832 reduces hypoxia in tumors expressing activated H-ras. Cancer Res 61: 2289-2293, 2001.
67. Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
68. Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., Randlev, B., Gillenwater, A. M., Bruso, P., Kaye, S. B., Hong, W. K., and Kirn, D. H. a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med., 6: 879-885, 2000.
69. Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Maples, P., Romel, L., Randlev, B., Reid, T., Kaye, S., and Kirn, D. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an EIB-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res., 60: 6359-6366, 2000.
70. Ishida, S., Yamashita, T., Nakaya, U., and Tokino, T. Adenovirus-mediated transfer of p53-related genes induces apoptosis of human cancer cells. Jpn. J. Cancer Res., 91: 174-180, 2000.
71. Clayman, G. L., el-Naggar, A. K., Lippman, S. M., Henderson, Y. C., Frederick, M., Merritt, J. A., Zumstein, L. A., Timmons, T. M., Liu, T. J., Ginsberg, L., Roth, J. A., Hong, W. K., Bruso, P., and Goepfert, H. Adenovirus-mediated p53 gene transfer in patients with advanced recurrent head and neck squamous cell carcinoma. J. Clin. Oncol., 16: 2221-2232, 1998.
72. Patel, V., Senderowicz, A. M., Pinto, D., Jr., Igishi, T., Raffeld, M., Quintanilla-Martinez, L., Ensley, J. F., Sausville, E. A., and Gutkind, J. S. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. J. Clin. Investig., 102: 1674-1681, 1998.
73. Kortmansky, J. S., Motwani, M. V., Jung, C. P., Matei, C., Koutcher, J. A., Gonen, M., Sirotnak, F. M., and Gary, S. L. Flavoperidol potentiates the effect of radiotherapy in HCT-116 colon cancer xenografts (abstract #347). Proc. Am. Soc. Clin. Oncol., 87a, 2002.
74. Schwartz, G. K., Farsi, K., Maslak, P., Kelsen, D. P., and Spriggs, D. Potentiation of apoptosis by flavopiridol in mitomycin-C-treated gastric and breast cancer cells. Clin. Cancer Res., 3: 1467-1472, 1997.
75. Schwartz, G. K., Ilson, D., Saltz, L., O'Reilly, E., Tong, W., Maslak, P., Werner, J., Perkins, P., Stoltz, M., and Kelsen, D. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J. Clin. Oncol., 19: 1985-1992, 2001.
76. Senderowicz, A. M. Small molecule modulators of cyclin-dependent kinases for cancer therapy. Oncogene, 19: 6600-6606, 2000.
77. Hashemolhosseini, S., Nagamine, Y., Morley, S. J., Desrivieres, S., Mercep, L., and Ferrari, S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J. Biol. Chem., 273: 14424-14429, 1998.
78. Hudson, C. C., Liu, M, Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., and Abraham, R. T. Regulation of hypoxia-inducible factor 1α expression and function by the mammalian target of rapamycin. Mol. Cell. Biol., 22: 7004-7014, 2002.
79. Kim, E. S., Hong, W. K., and Khuri, F. R. Chemoprevention of aerodigestive tract cancers. Annu. Rev. Med., 53: 223-243, 2002.
80. Rosas, S. L., Koch, W., da Costa Carvalho, M. G., Wu, L., Califano, J., Westra, W., Jen, J., and Sidransky, D. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res., 61: 939-942, 2001.
81. Sanchez-Cespedes, M., Esteller, M., Wu, L., Nawroz-Danish, H., Yoo, G. H., Koch, W. M., Jen, J., Herman, J. G., and Sidransky, D. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res., 60: 892-895, 2000.
82. Fliss, M. S., Usadel, H., Caballero, O. L., Wu, L., Buta, M. R., Eleff, S. M., Jen, J., and Sidransky, D. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science (Wash. DC), 287: 2017-2019, 2000.
83. Petricoin, E. F., Ardekani, A. M., Hitt, B. A., Levine, P. J., Fusaro, V. A., Steinberg, S. M., Mills, G. B., Simone, C., Fishman, D. A., Kohn, E. C., and Liotta, L. A. Use of proteomic patterns in serum to identify ovarian cancer. Lancet, 359: 572-577, 2002.
84. Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., Vaughan, C., and et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med., 315, 1501-1505, 1986.
85. Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C., and Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl. Cancer Inst., 86: 140-141, 1994.
86. Shin, D. M., Khuri, F. R., Murphy, B., Garden, A. S., Clayman, G., Francisco, M., Liu, D., Glisson, B. S., Ginsberg, L., Papadimitrakopoulou, V., Myers, J., Morrison, W., Gillenwater, A., Ang, K. K., Lippman, S. M., Goepfert, H., and Hong, W. K. Combined interferon-alfa, 13-cis-retinoic acid, and α-tocopherol in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J. Clin. Oncol., 19: 3010-3017, 2001.
87. Chan, G., Boyle, J. O., Yang, E. K., Zhang, F., Sacks, P. G., Shah, J. P., Edelstein, D, Soslow, R. A., Koki, A. T., Woerner, B. M., Masferrer, J. L., and Dannenberg, A. J. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res., 59: 991-994, 1999.
88. Shiotani, H., Denda, A., Yamamoto, K., Kitayama, W., Endoh, T., Sasaki, Y., Tsutsumi, N., Sugimura, M., and Konishi, Y. Increased expression of cyclooxygenase-2 protein in 4-nitroquinoline-1-oxide-induced rat tongue carcinomas and chemopreventive efficacy of a specific inhibitor, nimesulide. Cancer Res., 61: 1451-1456, 2001.
89. Cohen, E. E., Papadimitrakopoulou, V. A., Silverman, S., Jesse, M., Thomas, M., Kirn, D., Hong, W. K., Vokes, E. E., and Rudin, C. M. A phase II trial of attenuated adenovirus, Onyx-015, as mouthwash therapy for premalignant oral dysplasia (abstract 915). Proc. Am. Soc. Clin. Oncol., 229a, 2001.
90. Mork, J., Lie, A. K., Glattre, E., Hallmans, G., Jellum, E., Koskela, P., Moller, B., Pukkala, E., Schiller, J. T., Youngman, L., Lehtinen, M., and Dillner, J. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N. Engl. J. Med., 344: 1125-1131, 2001.
91. Harro, C. D., Pang, Y. Y., Roden, R. B., Hildesheim, A., Wang, Z., Reynolds, M. J., Mast, T. C., Robinson, R., Murphy, B. R., Karron, R. A., Dillner, J., Schiller, J. T., and Lowy, D. R. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst., 93: 284-292, 2001.
92. Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Chiacchierini, L. M., and Jansen, K. U. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med., 347: 1645-1651, 2002.